New preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at the AHA Scientific Sessions 2024
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced new preclinical data indicating that drug candidate CS585, a novel prostacyclin (IP) receptor agonist, inhibits platelet activation and clot formation up to 24 hours post-administration. The new data was presented at the AHA Scientific Sessions 2024, in Chicago on November 16, 2024.“We are delighted to present additional data for our preclinical asset CS585, demonstrating that the drug candidate, a